Bristol-Myers commits up to $475m for F-star option
This article was originally published in Scrip
Executive Summary
With a commitment worth up to $475m from Bristol-Myers Squibb for an option to acquire F-star Alpha, parent company F-star has a buyer for the first antibody spun out into a separate asset development vehicle under a strategy the Cambridge, UK-based firm established last year.